Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIMOTOP vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits calcium influx into vascular smooth muscle cells, leading to vasodilation. It has a preferential effect on cerebral arteries, reducing the incidence of vasospasm following subarachnoid hemorrhage.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms,Off-label: Prevention of cerebral vasospasm after subarachnoid hemorrhage, treatment of migraine, and cluster headaches
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
60 mg orally every 4 hours for 21 days, initiated within 96 hours of subarachnoid hemorrhage. If unable to swallow, 0.5 mg/h continuous IV infusion via central line; increase to 1 mg/h after 2 hours if tolerated, continue for up to 21 days.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life is approximately 8–9 hours (range 3–12 hours) in adults, with clinical context of twice-daily dosing for continuous cerebral vasodilation in subarachnoid hemorrhage.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Nimodipine is extensively metabolized in the liver primarily by the CYP3A4 isoenzyme, with no significant first-pass effect. Metabolites are excreted mainly in bile (about 80%) and urine (about 20%).
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily hepatic metabolism; 50% excreted in urine as metabolites, 30% in feces via biliary elimination. Less than 1% excreted unchanged in urine.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
97–99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Volume of distribution is 0.9–1.6 L/kg (average 1.2 L/kg), indicating extensive tissue distribution and high lipophilicity.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral: 13% (range 3–30%) due to extensive first-pass metabolism. Intravenous: 100%.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
No dose adjustment required for renal impairment. Use caution in severe renal failure due to risk of accumulation of metabolites.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Contraindicated in severe hepatic impairment (Child-Pugh C). In mild to moderate (Child-Pugh A or B), reduce oral dose to 30 mg every 4 hours or decrease IV infusion rate to 0.5 mg/h; monitor blood pressure closely.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Safety and efficacy not established in pediatric patients; no recommended dosing.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
No specific dose adjustment required, but elderly patients may be more sensitive to hypotensive effects; monitor blood pressure closely and consider starting at lower end of dosing range.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
No FDA black box warning.
None
Hypotension: May cause systemic hypotension, especially in patients with compromised cardiovascular function,Hepatic impairment: Reduce dose in patients with liver cirrhosis due to increased bioavailability,Intestinal pseudo-obstruction: Rare cases reported; monitor for decreased bowel sounds or abdominal distension
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to nimodipine or any component of the formulation,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) or inducers (e.g., rifampin, phenytoin, carbamazepine)
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Avoid grapefruit juice and grapefruit products as they inhibit CYP3A4 and increase nimodipine levels. Avoid high-fat meals as they may decrease absorption.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Teratogenicity not established in humans; animal studies show no fetal harm. Use only if maternal benefit outweighs risk. First trimester: avoid unless essential. Second/third trimesters: potential for maternal hypotension and reduced uteroplacental perfusion.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Excreted in breast milk; M/P ratio unknown. Use with caution; monitor infant for hypotension and bradycardia.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
No standard dose adjustments established. Monitor for hypotension; consider dose reduction if severe maternal hypotension occurs.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Administer via central line to avoid phlebitis; titrate slowly to avoid hypotension; monitor for bradycardia and heart block; use nifedipine (dihydropyridine) with caution in patients with hepatic impairment due to CYP3A4 metabolism.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take exactly as prescribed, do not skip doses.,Avoid grapefruit juice and grapefruit products during treatment.,Report any unusual bleeding, bruising, or signs of infection immediately.,Do not drive or operate heavy machinery if you feel dizzy or lightheaded.,Store capsules at room temperature away from moisture and heat.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIMOTOP vs ADALAT, answered by our medical review team.
NIMOTOP is a Calcium Channel Blocker that works by Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits calcium influx into vascular smooth muscle cells, leading to vasodilation. It has a preferential effect on cerebral arteries, reducing the incidence of vasospasm following subarachnoid hemorrhage.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIMOTOP and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIMOTOP is: 60 mg orally every 4 hours for 21 days, initiated within 96 hours of subarachnoid hemorrhage. If unable to swallow, 0.5 mg/h continuous IV infusion via central line; increase to 1 mg/h after 2 hours if tolerated, continue for up to 21 days.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIMOTOP and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIMOTOP is classified as Category C. Teratogenicity not established in humans; animal studies show no fetal harm. Use only if maternal benefit outweighs risk. First trimester: avoid unless essential. Second/third trim. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.